This database contains 283 studies, archived under the term: "diagnosis"
Click here to filter this large number of results.
Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study
Beauchet, Olivier,
Launay, Cyrille P.,
Allali, Gazan,
Watfa, Gilles,
Gallouj, Karim,
Herrmann, François R.,
Annweiler, Cedric
Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented patients with Alzheimer’s disease and related disorders (ADRD) before […]
Pain and distress in advanced dementia: choosing the right tools for the job
Objective: There is a concern that pain is under-recognized in dementia. However, there may be other causes of distress. We wished to evaluate the utility of a distress tool and a pain tool.; Methods: Nursing home residents with advanced dementia were observed using pain (Pain Assessment in Advanced Dementia scale (PAINAD)) and distress (Disability Distress […]
Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson’s disease
Witt, Karsten,
Daniels, Christine,
Krack, Paul,
Volkmann, Jens,
Pinsker, Markus O.,
Kloss, Manja,
Tronnier, Volker,
Schnitzler, Alfons,
Wojtecki, Lars,
Bötzel, Kai,
Danek, Adrian,
Hilker, Rüdiger,
Sturm, Volker,
Kupsch, Andreas,
Karner, Elfriede,
Deuschl, Günther
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) significantly improves quality of life (QoL) in Parkinson’s disease (PD). Dementia is considered as a contraindication for STN-DBS. However, no controlled study assessed the impact of STN-DBS on the QoL and motor outcome in PD patients with a borderline global cognitive impairment. We studied clinical baseline […]
Goal-oriented cognitive rehabilitation in early-stage dementia: study protocol for a multi-centre single-blind randomised controlled trial (GREAT)
Clare, Linda,
Bayer, Antony,
Burns, Alistair,
Corbett, Anne,
Jones, Roy,
Knapp, Martin,
Kopelman, Michael,
Kudlicka, Aleksandra,
Leroi, Iracema,
Oyebode, Jan,
Pool, Jackie,
Woods, Bob,
Whitaker, Rhiannon
Background: Preliminary evidence suggests that goal-oriented cognitive rehabilitation (CR) may be a clinically effective intervention for people with early-stage Alzheimer’s disease, vascular or mixed dementia and their carers. This study aims to establish whether CR is a clinically effective and cost-effective intervention for people with early-stage dementia and their carers.; Methods/design: In this multi-centre, single-blind […]
The Indiana University Cognitive Health Outcomes Investigation of the Comparative Effectiveness of dementia screening (CHOICE) study: study protocol for a randomized controlled trial
Fowler, Nicole R.,
Harrawood, Amanda,
Frame, Amie,
Perkins, Anthony J.,
Gao, Sujuan,
Callahan, Christopher M.,
Sachs, Greg A.,
French, Dustin D.,
Boustani, Malaz A.
Background: Dementia affects over 4 million people in the US and is frequently unrecognized and underdiagnosed in primary care. Routine dementia screening in primary care is not recommended by the US Preventive Services Task Force due to lack of empirical data on the benefits and harms of screening. This trial seeks to fill this gap […]
Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer’s disease
Fehlbaum-Beurdeley, Pascale,
Sol, Olivier,
Désiré, Laurent,
Touchon, Jacques,
Dantoine, Thierry,
Vercelletto, Martine,
Gabelle, Audrey,
Jarrige, Anne-Charlotte,
Haddad, Raphaël,
Lemarié, Jean Christophe,
Zhou, Weiyin,
Hampel, Harald,
Einstein, Richard,
Vellas, Bruno
Biomarkers have gained an increased importance in the past years in helping physicians to diagnose Alzheimer’s disease (AD). This study was designed to identify a blood-based, transcriptomic signature that can differentiate AD patients from control subjects. The performance of the signature was then evaluated for robustness in an independent blinded sample population. RNA was extracted […]
Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin
Endres, Kristina,
Fahrenholz, Falk,
Lotz, Johannes,
Hiemke, Christoph,
Teipel, Stefan,
Lieb, Klaus,
Tüscher, Oliver,
Fellgiebel, Andreas
Objective: We investigated induction of α-secretase A disintegrin and metalloprotease 10 (ADAM10) by the synthetic retinoid acitretin (Neotigason; Actavis, München-Riem, Germany) in patients with mild to moderate Alzheimer disease (AD) via measurement of CSF content of α-secretase-derived amyloid precursor protein (APPs-α).; Methods: Twenty-one patients clinically diagnosed with mild to moderate AD received acitretin (30 mg […]